Video

Studies Show Acalabrutinib Is Well-Tolerated in Patients with CLL

Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections

In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed exciting new findings being presented at the American Society of Hematology 2021 Annual Meeting about adverse effects associated with acalabrutinib in patients with chronic lymphocytic leukemia (CLL).

Andre said most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections. However, researchers found much lower rates of hypertension, cardiac arrhythmias, and bleeding events compared to what would be seen in earlier versions of the molecule class.

Related Videos
Lipoprotein particles | Image Credit: © komgritch - stock.adobe.com
Hands holding a crochet heart | Image Credit: © StockerThings - stock.adobe.com
Wooden blocks spelling HDL, LDL | Image Credit: © surasak - stock.adobe.com
Anticoagulant attacking blood clot | Image Credit: © BURIN93 - stock.adobe.com
Depiction of man aging | Image Credit: © Top AI images - stock.adobe.com
Map with pins | Image Credit: © Tryfonov - stock.adobe.com
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Image Credit: © abricotine - stock.adobe.com